Max Masucci
Stock Analyst at TD Cowen
(0.04)
# 4,146
Out of 4,829 analysts
23
Total ratings
10%
Success rate
-39.62%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $40.26 | +78.84% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $23.89 | +4.65% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $41.66 | +27.22% | 1 | Feb 24, 2023 | |
| HOLX Hologic | Maintains: Outperform | $86 → $95 | $58.81 | +61.54% | 2 | Feb 2, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $5.73 | +214.14% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $0.36 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $4.16 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $0.73 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $2.28 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $3.01 | - | 1 | Aug 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.94 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $7.06 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.17 | +2,045.92% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $81.26 | +478.39% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $5.80 | +331.03% | 1 | Apr 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $145 | $53.40 | +171.54% | 2 | Oct 28, 2020 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $40.26
Upside: +78.84%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $23.89
Upside: +4.65%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $41.66
Upside: +27.22%
Hologic
Feb 2, 2023
Maintains: Outperform
Price Target: $86 → $95
Current: $58.81
Upside: +61.54%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $5.73
Upside: +214.14%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $0.36
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.16
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.73
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.28
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.01
Upside: -
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.94
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.06
Upside: -
May 11, 2021
Initiates: Buy
Price Target: $25
Current: $1.17
Upside: +2,045.92%
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $81.26
Upside: +478.39%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $5.80
Upside: +331.03%
Oct 28, 2020
Maintains: Buy
Price Target: $120 → $145
Current: $53.40
Upside: +171.54%